Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of heterocyclic derivatives having cardiomyocyte proliferative activity for treatment of heart diseases

A technology for cardiomyocytes and uses, applied in the field of medical technology and medicine, can solve the problem of not being able to replace cardiomyocytes

Pending Publication Date: 2022-05-13
SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing treatment temporarily improves heart function but does not replace lost heart muscle cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of heterocyclic derivatives having cardiomyocyte proliferative activity for treatment of heart diseases
  • Use of heterocyclic derivatives having cardiomyocyte proliferative activity for treatment of heart diseases
  • Use of heterocyclic derivatives having cardiomyocyte proliferative activity for treatment of heart diseases

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0117] The present invention provides processes for the preparation of compounds of formula (I). The compounds of the present invention can be readily prepared by various synthetic procedures familiar to those skilled in the art. Exemplary preparations of these compounds may include, but are not limited to, the procedures described below.

[0118] Generally, in the preparation process, each reaction is generally carried out in an inert solvent at room temperature to reflux temperature (eg, 0-150°C, preferably 0-100°C). The reaction time is usually 0.1 to 60 hours, preferably 0.5 to 48 hours.

[0119] Preferably, the compounds of formula (I) of the present invention can be prepared with reference to the following schemes. In practice, the steps of the method can be extended or combined as desired.

[0120] plan 1

[0121]

[0122] The scheme shows one route that can be used to obtain the targets synthesized in this patent. Intermediate I-1 can be used as described in Ro...

Embodiment 1

[0149] Example 1: (Z)-5-(benzo[d][1,3]dioxol-5-ylmethylene)-2-(methyl(phenyl)amino)-3, 5-Dihydro-4H-imidazol-4-one

[0150]

[0151] To a solution of benzo[d][1,3]dioxol-5-ylmethanol (10.0 g, 65.7 mmol) in DCM (150 mL) was added activated MnO 2 (57.0 g, 657 mmol) and the mixture was stirred at 40 °C for 17 h. After filtration, the filtrate was concentrated to give benzo[d][1,3]dioxol-5-carbaldehyde (9.8 g, 99%) as a white solid, which was used in the next step without further purification. LRMS(M+H + ) m / z calculated value 151.0, measured value 151.0.

[0152]

[0153] To 2-thioimidazolidin-4-one (1.9 g, 17 mmol) and benzo[d][1,3]dioxol-5-carbaldehyde (3.0 g, 20.4 mmol) in toluene (30 mL) Piperidine (71 mg, 0.85 mmol) was added to the mixture in , and the mixture was stirred at 120 °C for 19 h. After concentration, the residue was recrystallized from DCM (30 mL) to give (Z)-5-(benzo[d][1,3]dioxol-5-ylmethylene)-2- Thioimidazolidin-4-one (3.8 g, 90%) as a yellow sol...

Embodiment 2

[0156] Example 2: (Z)-5-(benzo[d][1,3]dioxol-5-ylmethylene)-3-benzyl-2-(benzyl(phenyl) amino)-3,5-dihydro-4H-imidazol-4-one

[0157]

[0158]

[0159] To (Z)-5-(benzo[d][1,3]dioxol-5-ylmethylene)-2-(phenylamino)-3,5-diol at room temperature To a mixture of hydrogen-4H-imidazol-4-one (46 mg, 0.15 mmol), benzyl alcohol (21 mg, 0.195 mmol) and triphenylphosphine (59 mg, 0.225 mmol) in THF (1 mL) was added DIAD (46 mg, 0.225 mmol) mmol). in N 2Under protection, the mixture was stirred at room temperature for 21 h. The reaction mixture was concentrated and the residue was purified by silica gel flash chromatography (EA / PE=1 / 1, v / v) to give (Z)-5-(benzo[d][1,3]dioxane Penten-5-ylmethylene)-3-benzyl-2-(benzyl(phenyl)amino)-3,5-dihydro-4H-imidazol-4-one (10 mg, 9%) as Yellow solid.

[0160] LRMS(M+H + ) m / z calculated value 488.2, measured value 488.2. 1 H NMR(400MHz,DMSO-d6)δ7.29-6.95(m,16H),6.60(t,J=20.0Hz,3H),6.08(s,2H),4.79(s,2H),4.34(s, 2H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided is the use of a novel heterocyclic derivative having cardiomyocyte proliferative activity for the treatment of heart diseases. Specifically, disclosed are compounds of formula (I) or pharmaceutically acceptable salts, solvates, stereoisomers or prodrugs thereof; and their use. The definition of each group in the formula can be detailed in the specification.

Description

[0001] Field of Invention [0002] The invention belongs to the field of medical technology and medicine, and particularly relates to the use of a heterocyclic derivative with cardiomyocyte proliferation activity for treating heart disease. Background technique [0003] Events leading to a heart attack can be fatal. Most heart attacks are caused by the death of heart muscle cells, which disables the heart muscle's ability to pump blood, causing the organ to suffocate due to lack of oxygen. This can eventually lead to organ failure and potentially death. Preventing a heart attack often means detecting the underlying condition early and trying to intervene before it happens. It is known that in the event that a heart attack does occur, if one can regrow cells and replace dead cells in the heart, the heart attack is not fatal. However, after a narrow proliferation window in the neonatal stage, adult cardiomyocytes almost lose the ability to undergo cell division and proliferat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4166A61K31/4178C07D233/96A61P9/00A61P9/10
CPCA61P9/00A61K31/4178A61P9/10A61K31/4166A61K31/5377A61K31/4439
Inventor 陈义汉梁丹丹刘懿苏博斯李丽张芙蕾周慧星何晓雨
Owner SHANGHAI EAST HOSPITAL EAST HOSPITAL TONGJI UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com